Journal
JOURNAL OF MAGNETIC RESONANCE IMAGING
Volume 39, Issue 5, Pages 1259-1264Publisher
WILEY
DOI: 10.1002/jmri.24281
Keywords
gadobenate dimeglumine; MRI; gadoxetate disodium; hepatocellular adenoma
Ask authors/readers for more resources
Purpose To evaluate the presentation of inflammatory hepatocellular adenomas (HCAs) on hepatocyte phase MRI. Materials and Methods We retrospectively reviewed the MRI features of histologically proven HCAs on hepatocyte phase imaging. Twenty-one lesions (17 with inflammatory subtype) were scanned with gadobenate dimeglumine. Signal intensities of the lesions were assessed in the hepatocyte phase and on the T1-weighted sequences before contrast. Results After gadobenate dimeglumine injection, 71% (12/17) of the inflammatory HCAs showed areas of iso- or hyperintensity to the surrounding liver in the hepatocyte phase. In 82% (10/12) of the iso- or hyperintense lesions, this was found over more than 75% of the lesion surface. None of the noninflammatory HCAs showed areas of iso- or hyperintensity to the surrounding liver in the hepatocyte phase. From these 12, 7 were hyperintense on T1-weighting before contrast due to liver steatosis, 2 due to intrinsic hyperintensity (on the in-phase sequence), and 3 were isointense. Conclusion In contrast to noninflammatory HCAs, inflammatory HCAs can show areas of iso- to hyperintensity to the surrounding liver in the hepatocyte phase; therefore, other typical imaging features should also be used to distinguish between HCAs and FNHs. J. Magn. Reson. Imaging 2014;39:1259-1264. (c) 2013 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available